OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer

home / the-talk / breast-cancer-talk-nursing-perspectives-on-her2-targeted-agents-in-breast-cancer

Advertisement
Practical Management of Early Stage HER2+ Breast Cancer

EP. 1: Practical Management of Early Stage HER2+ Breast Cancer

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
  • Susan Hays, ANP, Washington University Siteman Cancer Center
  • Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020
HER2-targeted Therapy: Routes of Administration

EP. 2: HER2-targeted Therapy: Routes of Administration

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
  • Susan Hays, ANP, Washington University Siteman Cancer Center
  • Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

EP. 3: FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
  • Susan Hays, ANP, Washington University Siteman Cancer Center
  • Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020
Management of Adverse Effects in R/R HER2+ mBC

EP. 4: Management of Adverse Effects in R/R HER2+ mBC

By Madelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
  • Susan Hays, ANP, Washington University Siteman Cancer Center
  • Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute
September 23rd 2020

Latest Conference Coverage

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact